Casiopeina II-gly and bromo-pyruvate inhibition of tumor hexokinase, glycolysis, and oxidative phosphorylation

Archives of Toxicology

Volumn 86, Issue 5, 2012, Pages 753-766

  Marín Hernández, Alvaro ^a   Gallardo Pérez, Juan Carlos ^a   López Ramírez, Sayra Y ^a   García García, Jorge Donato ^a   Rodríguez Zavala, José Salud ^a   Ruiz Ramírez, Lena ^b   Gracia Mora, Isabel ^b   Zentella Dehesa, Alejandro ^c,d   Sosa Garrocho, Marcela ^d   MacÍas Silva, Marina ^b   Moreno Sánchez, Rafael ^a   Rodríguez Enríquez, Sara ^a,e  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

^e INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Bromopyruvate; Casiopeina; Cisplatin; Fast growing tumor cells; Glycolysis; Hexokinase

Indexed keywords

6 PHOSPHOFRUCTOKINASE; 6 PHOSPHOFRUCTOKINASE 1; ANTINEOPLASTIC AGENT; BROMOPYRUVIC ACID; CASIOPEINA II GLY; CISPLATIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOGEN; LACTIC ACID; MITOCHONDRIAL ENZYME; PHOSPHOGLYCERATE KINASE; PYRUVATE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL STRAIN; CELL STRAIN HUVEC; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GLYCOLYSIS; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; LYMPHOCYTE PROLIFERATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENERGY METABOLISM; GLYCOGEN; GLYCOLYSIS; HEXOKINASE; HUMANS; LACTATES; LYMPHOCYTES; ORGANOMETALLIC COMPOUNDS; OXIDATIVE PHOSPHORYLATION; PHOSPHOFRUCTOKINASE-1; PYRUVATE KINASE; PYRUVATES; RATS;

RODENTIA;

EID: 84862837100     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-012-0809-3     Document Type: Article

References (66)

1. Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM, Spaulding MB (1998) Staging of primary colorectal carcinomas with Xuorine-18 Xuorodeoxyglucose whole-body PET: correlation with histopathologic and CT Wndings. Radiology 206:755-760
2. Alemón-Medina R, Bravo-Gómez ME, Gracia-Mora MI, Ruiz-Azuara L (2011) Comparison between the antiproliferative eVect and intracellular glutathione depletion induced by Casiopeína IIgly and cisplatin in murine melanoma B16 cells. Toxicol In Vitro 25:868-873
3. Arendt T, Schugens MM, Marchbanks RM (1990) Reversible inhibition of acetylcholine synthesis and behavioural eVects caused by 3-bromopyruvate. J Neurochem 55:1474-1479
4. Aull JL, Allen RL, Bapat AR, Daron HH, Friedman ME, Wilson JF (1979) The eVects of platinum complexes on seven enzymes. Biochim Biophys Acta 571:352-358
5. Baker FL, Spitzer G, Ajani JA, Brock WA, Lukeman J, Pathak S, Tomasovic B, Thielvoldt D, Williams M, Vines C, ToWlon P (1986) Drug and radiation sensitivity measurements of successful primary monolayer culturing of human tumor cells using cell-adhesive matrix and supplemented medium. Cancer Res 46:1263-1274
6. Bergmeyer HU (1974) Methods of enzymatic analysis, 2nd edn. Verlag Chemie, New York
7. Boulard M, Blume KG, Beutler E (1972) The eVect of copper on red cell enzyme activities. J Clin Invest 51:459-461
8. Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, Mueller-Klieser W (2001) Elevated tumor lactate concentrations predict for an increased risk of metastases in head-andneck cancer. Int J Radiat Oncol Biol Phys 51:349-353
9. Cao X, Bloomston M, Zhang T, Frankel WL, Jia G, Wang B, Hall NC, Koch RM, Cheng H, Knopp MV, Sun D (2008) Synergistic antipancreatic tumor eVect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res 14:1831-1839
10. Carew JS, Huang P (2002) Mitochondrial defects in cancer. Mol Cancer 1:9
11. Chen Z, Zhang H, Lu W, Huang P (2009) Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim Biophys Acta 1787:553-560
12. Connolly BA, Trayer IP (1979) AYnity labelling of rat-muscle hexokinase type II by a glucose-derived alkylating agent. Eur J Biochem 93:375-383
13. Czernin J, Phelps ME (2002) Positron emission tomography scanning: current and future applications. Annu Rev Med 53:89-112
14. De Vizcaya-Ruiz A, Rivero-Muller A, Ruiz-Ramirez L, Kass GE, Kelland LR, Orr RM, Dobrota M (2000) Induction of apoptosis by a novel copper-based anticancer compound, casiopeina II, in L1210 murine leukaemia and CH1 human ovarian carcinoma cells. Toxicol In Vitro 14:1-5
15. Dell'Antone P (2006) Inactivation of H+ -vacuolar ATPase by the energy blocker 3-bromopyruvate, a new antitumour agent. Life Sci 79:2049-2055
16. Dykens JA, Jamieson J, Marroquin L, Nadanaciva S, Billis PA, Will Y (2008a) Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobicallypoised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol 233:203-210
17. Dykens JA, Jamieson JD, Marroquin LD, Nadanaciva S, Xu JJ, Dunn MC, Smith AR, Will Y (2008b) In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 103:335-345
18. Ercan N, Gannon MC, Nuttall FQ (1996) Allosteric regulation of liver phosphorylase a: revisited under approximated physiological conditions. Arch Biochem Biophys 328:255-264
19. Ferlini C, Scambia G, Marone M, Distefano M, Gaggini C, Ferrandina G, Fattorossi A, Isola G, Benedetti Panici P, Mancuso S (1999) Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer 79:257-263
20. Fiorani M, De Sanctis R, Scarlatti F, Vallorani L, De Bellis R, SeraWni G, Bianchi M, Stocchi V (2000) Dehydroascorbic acid irreversibly inhibits hexokinase activity. Mol Cell Biochem 209:145-153
21. Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, De Martino C (1981) Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst 66:497-499
22. Gallardo-Perez JC, Espinosa M, Ceballos-Cancino G, Daniel A, Rodriguez-Enriquez S, Aviles A, Moreno-Sánchez R, Melendez-Zajgla J, Maldonado V (2009) NF-kappa B is required for the development of tumor spheroids. J Cell Biochem 108:169-180
23. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, Cole RN, Syed LH, Rao PP, Ota S, Vali M (2009) Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res 29:4909-4918
24. Gatenby RA, Gillies RJ (2007) Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol 39:1358-1366
25. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL (2002) Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62:3909-3913
26. Gornall AG, Bardawill CJ, David MM (1949) Determination of serum proteins by means of the biuret reaction. J Biol Chem 177:751-766
27. Hernández-Esquivel L, Marín-Hernández A, Pavon N, Carvajal K, Moreno-Sánchez R (2006) Cardiotoxicity of copper-based antineoplastic drugs casiopeinas is related to inhibition of energy metabolism. Toxicol Appl Pharmacol 212:79-88
28. Hue L, Bontemps F, Hers H (1975) The eVects of glucose and of potassium ions on the interconversion of the two forms of glycogen phosphorylase and of glycogen synthetase in isolated rat liver preparations. Biochem J 152:105-114
29. Hutny J, Wilson JE (1990) EVect of ligand-induced conformational changes on the reactivity of speciWc sulfhydryl residues in rat brain hexokinase. Arch Biochem Biophys 283:173-183
30. JaVe EA, Nachman RL, Becker CG, Minick CR (1973) Culture of human endothelial cells derived from umbilical veins. IdentiWcation by morphologic and immunologic criteria. J Clin Invest 52:2745-2756
31. Kachadourian R, Brechbuhl HM, Ruiz-Azuara L, Gracia-Mora I, Day BJ (2010) Casiopeina IIgly-induced oxidative stress and mitochondrial dysfunction in human lung cancer A549 and H157 cells. Toxicology 268:176-183
32. Kim JS, Ahn KJ, Kim JA, Kim HM, Lee JD, Lee JM, Kim SJ, Park JH (2008) Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells: ROS-mediated cell death by 3-BrPA. J Bioenerg Biomembr 40:607-618
33. Ko YH, Pedersen PL, Geschwind JF (2001) Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173:83-91
34. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL (2004) Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324:269-275
35. Lapela M, Grenman R, Kurki T, Joensuu H, Leskinen S, Lindholm P, Haaparanta M, Ruotsalainen U, Minn H (1995) Head and neck cancer: detection of recurrence with PET and 2-[F-18]Xuoro-2-deoxy-D-glucose. Radiology 197:205-211
36. Lawley PD, Phillips DH (1996) DNA adducts from chemotherapeutic agents. Mutat Res 355:13-40
37. López-Gómez FJ, Torres-Márquez ME, Moreno-Sánchez R (1993) Control of oxidative phosphorylation in AS-30D hepatoma mitochondria. Int J Biochem 25:373-377
38. Marín-Hernández A, Gracia-Mora I, Ruiz-Ramirez L, Moreno-Sánchez R (2003) Toxic eVects of copper-based antineoplastic drugs (Casiopeinas) on mitochondrial functions. Biochem Pharmacol 65:1979-1989
39. Marín-Hernández A, Rodríguez-Enríquez S, Vital-González PA, Flores-Rodríguez FL, Macias-Silva M, Sosa-Garrocho M, Moreno-Sánchez R (2006) Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase. FEBS J 273:1975-1988
40. Marín-Hernández A, Gallardo-Pérez JC, Rodríguez-Enríquez S, Encalada R, Moreno-Sánchez R, Saavedra E (2011) Modeling cancer glycolysis. Biochim Biophys Acta 1807:755-767
41. Mejia C, Ruiz-Azuara L (2008) Casiopeinas IIgly and IIIia induce apoptosis in medulloblastoma cells. Pathol Oncol Res 14:467-472
42. Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E (2007) Energy metabolism in tumor cells. FEBS J 274:1393-1418
43. Moreno-Sánchez R, Rodríguez-Enríquez S, Saavedra E, Marín-Hernández A, Gallardo-Pérez JC (2009) The bioenergetics of cancer: is glycolysis the main ATP supplier in all tumor cells? Biofactors 35:209-225
44. Ohnuma T, Arkin H, Holland JF (1986) EVects of cell density on druginduced cell kill kinetics in vitro (inoculum eVect). Br J Cancer 54:415-421
45. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, Kuyama J, Mikata A, Arimizu N (1992) Positron emission tomography using Xuorine-18-Xuorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 33:325-329
46. Pastorino JG, Hoek JB (2003) Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr Med Chem 10:1535-1551
47. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH (2002) Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 1555:14-20
48. Pelicano H, Martin DS, Xu RH, Huang P (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25:4633-4646
49. Penso J, Beitner R (2002) Detachment of glycolytic enzymes from cytoskeleton of Lewis lung carcinoma and colon adenocarcinoma cells induced by clotrimazole and its correlation to cell viability and morphology. Mol Genet Metab 76:181-188
50. Pereira da Silva AP, El-Bacha T, Kyaw N, dos Santos RS, da-Silva WS, Almeida FC, Da Poian AT, Galina A (2009) Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J 417:717-726
51. Robey IF, Lien AD, Welsh SJ, Baggett BK, Gillies RJ (2005) Hypoxiainducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 7:324-330
52. Robustelli della Cuna G, Pedrazzoli P (1991) Toxicity and clinical tolerance of lonidamine. Semin Oncol 18:18-22
53. Rodríguez-Enríquez S, Vital-González PA, Flores-Rodríguez FL, Marín-Hernández A, Ruiz-Azuara L, Moreno-Sánchez R (2006) Control of cellular proliferation by modulation of oxidative phosphorylation in human and rodent fast-growing tumor cells. Toxicol Appl Pharmacol 215:208-217
54. Rodríguez-Enríquez S, Marín-Hernández A, Gallardo-Pérez JC, Carreno-Fuentes L, Moreno-Sánchez R (2009) Targeting of cancer energy metabolism. Mol Nutr Food Res 53:29-48
55. Saavedra E, Encalada R, Pineda E, Jasso-Chávez R, Moreno-Sánchez R (2005) Glycolysis in Entamoeba histolytica. Biochemical characterization of recombinant glycolytic enzymes and Xux control analysis. FEBS J 272:1767-1783
56. Schwimmer J, Essner R, Patel A, Jahan SA, Shepherd JE, Park K, Phelps ME, Czernin J, Gambhir SS (2000) A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med 44:153-167
57. Simonnet H, Alazard N, PfeiVer K, Gallou C, Beroud C, Demont J, Bouvier R, Schagger H, Godinot C (2002) Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 23:759-768
58. Stalmans W, Laloux M, Hers HG (1974) The interaction of liver phosphorylase a with glucose and AMP. Eur J Biochem 49:415-427
59. Thomas JP, Lautermann J, Liedert B, Seiler F, Thomale J (2006) High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but in carboplatin toxicity. Mol Pharmacol 70:23-29
60. Tiedge M, Richter T, Lenzen S (2000) Importance of cysteine residues for the stability and catalytic activity of human pancreatic beta cell glucokinase. Arch Biochem Biophys 375:251-260
61. Torres NV, Mateo F, Sicilia J, Melendez-Hevia E (1988) Distribution of the Xux control in convergent metabolic pathways: theory and application to experimental and simulated systems. Int J Biochem 20:161-165
62. Trejo-Solís C, Palencia G, Zuniga S, Rodriguez-Ropon A, Osorio-Rico L, Luvia ST, Gracia-Mora I, Márquez-Rosado L, Sánchez A, Moreno-García ME, Cruz A, Bravo-Gómez ME, Ruiz-Ramirez L, Rodríguez-Enríquez S, Sotelo J (2005) Cas IIgly induces apoptosis in glioma C6 cells in vitro and in vivo through caspasedependent and caspase-independent mechanisms. Neoplasia 7:563-574
63. Vasta V, Bruni P, Farnararo M (1987) Mechanism of thrombin-induced rise in platelet fructose 2,6-bisphosphate content. Studies using phorbol myristate acetate, dioctanoylglycerol and ionophore A23187. Biochem J 244:547-551
64. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P (2005) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65:613-621
65. Yin J, Gao Z, Liu D, Liu Z, Ye J (2008) Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab 294:E148-E156
66. Yuan Z, Cao K, Lin C, Li L, Liu HY, Zhao XY, Liu L, Deng HX, Li J, Nie CL, Wei YQ (2011) PUMA chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1. Mol Med 17:1262-1274